Our analysis provides evidence that the cardiovascular outcomes trials examining novel diabetes medications (SGLT-2 Is1–4, DPP-4 Is5–8, and GLP-1 RAs9–16) were well powered to detect significant differences with respect to the primary endpoint (major adverse cardiovascular events) in the range that really occurred as the result of such clinical studies (15–25%; Fig. 2). The gene discussed is SLC5A2; the disease is diabetes mellitus.